SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive: SIRT1 is an interesting druggable target to halt tumor cell proliferation with successes in chronic myeloid leukemia [44] and with an inhibitor found to be safe in a clinical trial [45, 46].